<DOC>
	<DOCNO>NCT00665392</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody , cetuximab , block tumor growth different way . Some block ability tumor cell grow spread . Others find tumor cell help kill carry tumor-killing substance . Drugs use chemotherapy , docetaxel , cisplatin , fluorouracil , work different way stop growth tumor cell , either kill cell stop divide . Giving one drug ( combination chemotherapy ) together cetuximab may kill tumor cell . PURPOSE : This phase II clinical trial study well cetuximab give together combination chemotherapy work treat patient stage III stage IV oropharynx cancer remove surgery .</brief_summary>
	<brief_title>Cetuximab Combination Chemotherapy Treating Patients With Stage III Stage IV Oropharynx Cancer That Can Be Removed Surgery</brief_title>
	<detailed_description>OBJECTIVES : Primary - To determine complete clinical response rate 3 month patient stage III IV nonmetastatic squamous cell carcinoma oropharynx treat cetuximab , docetaxel , cisplatin , fluorouracil . Secondary - To determine rate tumor response . - To determine progression-free overall survival . - To determine rate complete pathological response . - To assess tolerability regimen patient . OUTLINE : This multicenter study . Patients receive cetuximab IV 1-2 hour day 1 , 8 , 15 ; docetaxel IV 1 hour cisplatin IV 1 hour day 1 ; fluorouracil IV continuously day 1-5 . Treatment repeat every 3 week 3 course absence disease progression unacceptable toxicity . After completion study therapy , patient follow every 2 month 1 year every 3 month 2 year .</detailed_description>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm squamous cell carcinoma oropharynx Stage III ( T3 T12 , N12 , M0 ) nonmetastatic stage IV ( T4 T13 , N3 , M0 ) disease Resectable disease Measurable evaluable disease Tumor tissue available PATIENT CHARACTERISTICS : Inclusion criterion : WHO performance status 01 ANC ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Hemoglobin ≥ 9 g/dL Creatinine &lt; 1.5 time upper limit normal ( ULN ) Creatinine clearance ≥ 60 mL/min AST ALT &lt; 5 time ULN Bilirubin &lt; 1.5 time ULN Not pregnant nursing Fertile patient must use effective contraception Affiliated social security ( include CMU ) Exclusion criterion : Cardiovascular accident ( myocardial infarction , cerebral vascular accident ) within past 6 month Serious and/or uncontrolled cardiac respiratory disease ( pulmonary fibrosis , interstitial pneumopathy ) Other cancer within past 5 year except resected skin cancer , localize cutaneous totally resected melanoma , resect carcinoma situ cervix Auditory condition preclude use cisplatin Contraindication due psychological , social , geographical reason may impede proper monitoring treatment Persons guardianship trusteeship , prisoner law PRIOR CONCURRENT THERAPY : No prior treatment , include chemotherapy radiotherapy No concurrent phenytoin , live attenuate vaccine , parenteral aminoglycosides</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>stage III squamous cell carcinoma oropharynx</keyword>
	<keyword>stage IV squamous cell carcinoma oropharynx</keyword>
	<keyword>tongue cancer</keyword>
</DOC>